In contrast, both KRAS wildtype Lc2/ad and SW48 cells had increased sensitivity to erlotinib treatment, and KRAS mutant CRC cells were resistant to this EGFR kinase inhibitor as predicted (Figure 2E) [16]. This evidence concerns the gene KRAS and colorectal carcinoma.